{
    "clinical_study": {
        "@rank": "43433", 
        "acronym": "SNAP", 
        "arm_group": [
            {
                "arm_group_label": "nab-Paclitaxel 150 mg/m2 days 1,15", 
                "arm_group_type": "Experimental", 
                "description": "Arm A: Induction nab-Paclitaxel 150 mg/m2 on days 1,8,15 every 28 days for 3 cycles  followed by maintenance nab-Paclitaxel  150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "nab-Paclitaxel 100 mg/m2 days 1,8,15", 
                "arm_group_type": "Experimental", 
                "description": "Arm B: Induction nab-Paclitaxel 150 mg/m2 on days 1,8,15 every 28 days for 3 cycles  followed by maintenance nab-Paclitaxel  100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "nab-Paclitaxel 75 mg/m2 days 1,8,15,22", 
                "arm_group_type": "Experimental", 
                "description": "Arm C: Induction nab-Paclitaxel 150 mg/m2 on days 1,8,15 every 28 days for 3 cycles  followed by maintenance nab-Paclitaxel  75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "Longer first line chemotherapy duration has recently been associated with a modest, but\n      significant improvement in overall survival and a clinically meaningful and statistically\n      significant improvement in progression-free survival, in metastatic breast cancer patients.\n      Prolonging chemotherapy until disease progression, however, must be weighed against the\n      detrimental effects of continuous chemotherapy delivery. The SNAP trial seeks to improve the\n      tolerability of prolonged chemotherapy administration strategy by studying alternative\n      treatment schedules, while preserving and possibly improving treatment efficacy in this\n      disease setting.\n\n      The availability of a new nanoparticle albumin-bound taxane, nab-Paclitaxel (Abraxane\u00ae),\n      represents an opportunity to test this hypothesis. Nab-Paclitaxel has been developed in an\n      attempt to reduce the toxicity associated with standard taxane administration (caused by the\n      use of chemical solvents) while increasing antitumor efficacy.\n\n      The SNAP randomized phase II trial evaluates three schedules of nab-Paclitaxel as prolonged\n      chemotherapy administration strategy. Each of three arms will be compared to a historical\n      reference of seven-month median progression-free survival (PFS) based on the most recent\n      trial with docetaxel as control arm to determine whether any of the three arms are worthy of\n      further investigation."
        }, 
        "brief_title": "Schedules of Nab-Paclitaxel in Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "April 2023", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer.", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed HER2-negative metastatic (stage IV) breast\n             cancer.\n\n          -  Measurable or non-measurable, but radiologically evaluable, disease according to\n             RECIST 1.1 criteria.\n\n          -  Female aged 18 years or older.\n\n          -  Life expectancy > 3 months.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n\n          -  Either ER-positive or ER-negative disease. Patients with ER-positive disease must be\n             endocrine resistant, defined as having failed at least one prior endocrine therapy\n             for breast cancer, or must be candidates for first-line chemotherapy.\n\n          -  If previously treated with a taxane or anthracycline in the neoadjuvant or adjuvant\n             setting, the period from end of treatment to disease recurrence must have been > 12\n             months (> 365 days).\n\n          -  Radiation therapy, if given and regardless of site, must be completed at least 2\n             weeks prior to randomization.\n\n          -  Normal hematologic status.\n\n          -  Normal renal function.\n\n          -  Normal liver function.\n\n          -  Normal cardiac function.\n\n          -  Women of childbearing potential: documented negative pregnancy test within 2 weeks\n             prior to randomization, and acceptable birth control during the duration of the trial\n             therapy and for a period of 6 months following the last administration of study drug.\n\n          -  Written Informed Consent (IC) must be signed and dated by the patient and the\n             Investigator prior to randomization.\n\n          -  Completed baseline Quality of Life Form.\n\n          -  The patient has been informed of and agrees to data transfer and handling, in\n             accordance with national data protection guidelines.\n\n          -  Availability of an formalin fixed paraffin embedded (FFPE) block from the primary\n             tumor (breast lesion) for submission to central pathology review and for\n             translational research.\n\n          -  Written consent to pathology material submission, signed and dated by the patient and\n             the Investigator prior to randomization.\n\n        Exclusion Criteria:\n\n          -  Any prior chemotherapy for metastatic breast cancer.\n\n          -  Presence of central nervous system (CNS) metastasis.\n\n          -  Peripheral neuropathy grade 2 or higher (CTCAE version 4).\n\n          -  Significant uncontrolled cardiac disease (i.e. unstable angina, recent myocardial\n             infarction within prior 6 months), patients classified as having a New York Heart\n             Association (NYHA) class III or IV congestive heart failure.\n\n          -  Pregnant or lactating.\n\n          -  Prior history of non-breast malignancy (except for adequately controlled basal cell\n             carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the\n             bladder).\n\n          -  Any concurrent condition which in the Investigator's opinion makes it inappropriate\n             for the patient to participate in the trial or which would jeopardize compliance with\n             the protocol.\n\n          -  Contraindications or known hypersensitivity to the study medication or excipients.\n\n          -  The use of any anti-cancer investigational agents within 30 days prior to expected\n             start of trial treatment.\n\n          -  Inability or unwillingness to abide by the study protocol or cooperate fully with the\n             Investigator."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746225", 
            "org_study_id": "IBCSG 42-12/BIG 2-12", 
            "secondary_id": "2012-003058-10"
        }, 
        "intervention": {
            "arm_group_label": [
                "nab-Paclitaxel 150 mg/m2 days 1,15", 
                "nab-Paclitaxel 100 mg/m2 days 1,8,15", 
                "nab-Paclitaxel 75 mg/m2 days 1,8,15,22"
            ], 
            "description": "Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle,  different number of administrations)", 
            "intervention_name": "nab-Paclitaxel", 
            "intervention_type": "Drug", 
            "other_name": "Abraxane"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic", 
            "Breast", 
            "Cancer", 
            "HER2-negative Stage IV", 
            "No previous chemotherapy"
        ], 
        "lastchanged_date": "October 30, 2013", 
        "location": [
            {
                "contact": {
                    "email": "g.jerusalem@chu.ulg.ac.be", 
                    "last_name": "Guy Jerusalem, MD, PhD", 
                    "phone": "+32 43 667 664"
                }, 
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "CHU Sart Tilman, Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Guy Jerusalem, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jean.paul.salmon@chrcitadelle.be", 
                    "last_name": "Jean Paul Salmon, Dr", 
                    "phone": "+32 42 25 64 45"
                }, 
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "CHR de la Citadelle, Oncology-Haematology Unit"
                }, 
                "investigator": {
                    "last_name": "Jean Paul Salmon, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "annelore.barbeaux@chplt.be", 
                    "last_name": "Annelore Barbeaux, MD", 
                    "phone": "+32 87 21 94 83"
                }, 
                "facility": {
                    "address": {
                        "city": "Verviers", 
                        "country": "Belgium", 
                        "zip": "4800"
                    }, 
                    "name": "Centre Hospitalier Peltzer-La Tourelle, Department of Clinical Cancerology"
                }, 
                "investigator": {
                    "last_name": "Annelore Barbeaux, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bryan.hennessy@hse.ie", 
                    "last_name": "Bryan Hennessy"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "Beaumont Hospital"
                }, 
                "investigator": {
                    "last_name": "Bryan Hennessy", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jkennedy@stjames.ie", 
                    "last_name": "John Kennedy"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "St James's Hospital"
                }, 
                "investigator": {
                    "last_name": "John Kennedy", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "janice.walshe@amnch.ie", 
                    "last_name": "Janice Walshe"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "St Vincent's University Hospital"
                }, 
                "investigator": {
                    "last_name": "Janice Walshe", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ckelly@mater.ie", 
                    "last_name": "Catherine Kelly"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "Mater Private Hospital"
                }, 
                "investigator": {
                    "last_name": "Catherine Kelly", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ckelly@mater.ie", 
                    "last_name": "Catherine Kelly"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "Mater Misericordiae University Hospital"
                }, 
                "investigator": {
                    "last_name": "Catherine Kelly", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lindae.coate@hse.ie", 
                    "last_name": "Linda Coate"
                }, 
                "facility": {
                    "address": {
                        "city": "Limerick", 
                        "country": "Ireland"
                    }, 
                    "name": "Mid-Western Regional Hospital"
                }, 
                "investigator": {
                    "last_name": "Linda Coate", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Miriam.OConnor2@hse.ie", 
                    "last_name": "Miriam O'Connor"
                }, 
                "facility": {
                    "address": {
                        "city": "Waterford", 
                        "country": "Ireland"
                    }, 
                    "name": "Waterford Regional Hospital"
                }, 
                "investigator": {
                    "last_name": "Miriam O'Connor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "plpiovano@ospedale.al.it", 
                    "last_name": "Pierluigi Piovano"
                }, 
                "facility": {
                    "address": {
                        "city": "Alessandria", 
                        "country": "Italy", 
                        "zip": "15121"
                    }, 
                    "name": "Azienda Ospedaliera SS Antonio e Biagio"
                }, 
                "investigator": {
                    "last_name": "Pierluigi Piovano", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alice.giacobino@poloncologico.org", 
                    "last_name": "Alice Giacobino"
                }, 
                "facility": {
                    "address": {
                        "city": "Biella", 
                        "country": "Italy", 
                        "zip": "13900"
                    }, 
                    "name": "Ospedale degli Infermi"
                }, 
                "investigator": {
                    "last_name": "Alice Giacobino", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "f.artioli@ausl.mo.it", 
                    "last_name": "Fabrizio Artioli"
                }, 
                "facility": {
                    "address": {
                        "city": "Carpi/ Modena", 
                        "country": "Italy", 
                        "zip": "41012"
                    }, 
                    "name": "Ospedale \"B. Ramazzini\""
                }, 
                "investigator": {
                    "last_name": "Fabrizio Artioli", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alessandra.gennari@galliera.it", 
                    "last_name": "Alessandra Gennari"
                }, 
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "zip": "16128"
                    }, 
                    "name": "E.O. Ospedali Galliera"
                }, 
                "investigator": {
                    "last_name": "Alessandra Gennari", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "marco.colleoni@ieo.it", 
                    "last_name": "Marco Colleoni"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Europeo di Oncologia (IEO)"
                }, 
                "investigator": {
                    "last_name": "Marco Colleoni", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lorenzo.pavesi@fsm.it", 
                    "last_name": "Lorenzo Pavesi"
                }, 
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "zip": "27100"
                    }, 
                    "name": "Fondazione Salvatore Maugeri"
                }, 
                "investigator": {
                    "last_name": "Lorenzo Pavesi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "giuseppe.naso@uniroma1.it", 
                    "last_name": "Giuseppe Naso"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Universita degli Studi di Roma La Sapienza"
                }, 
                "investigator": {
                    "last_name": "Giuseppe Naso", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "armando.santoro@humanitas.it", 
                    "last_name": "Armando Santoto"
                }, 
                "facility": {
                    "address": {
                        "city": "Rozzano", 
                        "country": "Italy", 
                        "zip": "20089"
                    }, 
                    "name": "Istituto Clinico Humanitas"
                }, 
                "investigator": {
                    "last_name": "Armando Santoro", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Elisa.Gallerani@multimedica.it", 
                    "last_name": "Elisa Gallerani"
                }, 
                "facility": {
                    "address": {
                        "city": "Sede di Castellanza", 
                        "country": "Italy", 
                        "zip": "21053"
                    }, 
                    "name": "IRCCS MultiMedica"
                }, 
                "investigator": {
                    "last_name": "Elisa Gallerani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "fabio.puglisi@uniud.it", 
                    "last_name": "Fabio Puglisi"
                }, 
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy", 
                        "zip": "33100"
                    }, 
                    "name": "Azienda Osp. Universitaria di Udine"
                }, 
                "investigator": {
                    "last_name": "Fabio Puglisi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sborstnar@onko-i.si", 
                    "last_name": "Simona Borstnar"
                }, 
                "facility": {
                    "address": {
                        "city": "Ljubljana", 
                        "country": "Slovenia", 
                        "zip": "1000"
                    }, 
                    "name": "Institute of Oncology"
                }, 
                "investigator": {
                    "last_name": "Simona Borstnar", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Christoph.Rochlitz@usb.ch", 
                    "last_name": "Christoph Rochlitz"
                }, 
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "4031"
                    }, 
                    "name": "Universit\u00e4tsspital Basel"
                }, 
                "investigator": {
                    "last_name": "Christoph Rochlitz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "olivia.pagani@ibcsg.org", 
                    "last_name": "Olivia Pagani"
                }, 
                "facility": {
                    "address": {
                        "city": "Bellinzona", 
                        "country": "Switzerland", 
                        "zip": "6500"
                    }, 
                    "name": "Instituto Oncologico della Svizzera Italiana"
                }, 
                "investigator": {
                    "last_name": "Olivia Pagani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "manuela.rabaglio@insel.ch", 
                    "last_name": "Manuela Rabaglio"
                }, 
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "3011"
                    }, 
                    "name": "Universit\u00e4tsspital/ Inselspital Bern"
                }, 
                "investigator": {
                    "last_name": "Manuela Rabaglio", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "markus.borner@szb-chb.ch", 
                    "last_name": "Markus Borner"
                }, 
                "facility": {
                    "address": {
                        "city": "Biel", 
                        "country": "Switzerland", 
                        "zip": "2501"
                    }, 
                    "name": "Spitalzentrum Biel"
                }, 
                "investigator": {
                    "last_name": "Markus Borner", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "roger.vonmoos@ksgr.ch", 
                    "last_name": "Roger von Moos"
                }, 
                "facility": {
                    "address": {
                        "city": "Chur", 
                        "country": "Switzerland", 
                        "zip": "7000"
                    }, 
                    "name": "Kantonsspital Graub\u00fcnden"
                }, 
                "investigator": {
                    "last_name": "Roger von Moos", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "stefan.aebi@onkologie.ch", 
                    "last_name": "Stefan Aebi"
                }, 
                "facility": {
                    "address": {
                        "city": "Luzern", 
                        "country": "Switzerland", 
                        "zip": "6000"
                    }, 
                    "name": "Luzerner Kantonsspital"
                }, 
                "investigator": {
                    "last_name": "Stefan Aebi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ursula.hasler-strub@kssg.ch", 
                    "last_name": "Ursula Hasler-Strub"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "9007"
                    }, 
                    "name": "Kantonsspital St. Gallen"
                }, 
                "investigator": {
                    "last_name": "Ursula Hasler-Strub", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "daniel.rauch@spitalstsag.ch", 
                    "last_name": "Rauch Daniel"
                }, 
                "facility": {
                    "address": {
                        "city": "Thun", 
                        "country": "Switzerland", 
                        "zip": "3600"
                    }, 
                    "name": "Onkologiezentrum Thun-Berner Oberland"
                }, 
                "investigator": {
                    "last_name": "Daniel Rauch", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andreas.mueller@ksw.ch", 
                    "last_name": "Andreas Mueller"
                }, 
                "facility": {
                    "address": {
                        "city": "Witerthur", 
                        "country": "Switzerland", 
                        "zip": "8401"
                    }, 
                    "name": "Kantonsspital Winterthur"
                }, 
                "investigator": {
                    "last_name": "Andreas Mueller", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Ireland", 
                "Italy", 
                "Slovenia", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial)", 
        "overall_official": [
            {
                "affiliation": "Division of Medical Oncology, E.O. Galliera, Genoa, Italy", 
                "last_name": "Alessandra Gennari, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CHU Sart Tilman and University of Li\u00e8ge, Li\u00e8ge, Belgium", 
                "last_name": "Guy Jerusalem, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Switzerland: Swissmedic", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Italy: The Italian Medicines Agency", 
                "Ireland: Irish Medicines Board", 
                "Slovenia: Agency for Medicinal Products - Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Disease response and progression will be evaluated according to the revised Response Evaluation Criteria in Solid Tumors (RECIST V 1.1) Patients may have measurable or non-measurable disease. CT can is the method to measure lesion.", 
            "measure": "Efficacy of nab-Paclitaxel schedules", 
            "safety_issue": "No", 
            "time_frame": "At the end of the third induction cycle and during maintenace nab-Paclitaxel every three months until PD (an expected average of nine months)"
        }, 
        "reference": [
            {
                "PMID": "17647245", 
                "citation": "Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'reilly SE, Olivotto IA. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007 Sep 1;110(5):973-9."
            }, 
            {
                "PMID": "16149088", 
                "citation": "Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005 Oct 15;104(8):1742-50."
            }, 
            {
                "PMID": "15310773", 
                "citation": "Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004 Aug 15;22(16):3302-8."
            }, 
            {
                "PMID": "18725649", 
                "citation": "Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4891-8. Epub 2008 Aug 25."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746225"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determination of targeted adverse events (AE), performance status, hematological/ biochemical examinations and physical exams are used to evaluate tolerability and feasibility, vital signs for overall survival (OS).", 
                "measure": "Tolerability, feasibility, disease response and OS of nab-Paclitaxel schedules", 
                "safety_issue": "Yes", 
                "time_frame": "Targeted AEs at the end of each cycle and  hematology days  1, 8, 15, 22 according to treatment arm"
            }, 
            {
                "description": "To explore the changes in quality of life (QL) over time until treatment discontinuation.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "QL self-assessment once each months until PD (maximal twelve months, expected average of nine months) and at end-of-treatment visit"
            }, 
            {
                "description": "To investigate the prognostic role of putative markers (SPARC and caveolin) and assess any change in the expression of SPARC and caveolin between primary and the metastatic sites.", 
                "measure": "Prognostic biomarker analysis", 
                "safety_issue": "No", 
                "time_frame": "SPARC and caveolin expressions will be determined in FFPE (formalin fixed paraffin embedded) samples from primary tumor (obtained 14 days prior to randomization) and from FFPE sample of metastatic biopsy at PD (an expected average of nine months)"
            }
        ], 
        "source": "International Breast Cancer Study Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "International Breast Cancer Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}